CADL
Candel Therapeutics Inc.
$5.38
-$0.20(-3.58%)
43
Overall
60
Value
40
Tech
31
Quality
Market Cap
$307.41M
Volume
837.42K
52W Range
$3.79 - $14.60
Target Price
$20.17
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $100.0K | $125.0K | -- | -- | ||
| Total Revenue | $100.0K | $125.0K | -- | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $100.0K | $125.0K | -- | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $25.9M | $34.8M | $38.4M | $33.4M | ||
| Research & Development | $15.2M | $20.8M | $24.5M | $19.3M | ||
| Research Expense | $15.2M | $20.8M | $24.5M | $19.3M | ||
| Selling, General & Administrative | $10.7M | $14.1M | $13.9M | $14.1M | ||
| General & Administrative Expenses | $10.7M | $14.1M | $13.9M | $14.1M | ||
| Salaries & Wages | -- | -- | $7.6M | $6.8M | ||
| Depreciation & Amortization | $200.0K | $800.0K | $1.0M | $1.0M | ||
| Depreciation & Amortization | $200.0K | $800.0K | $1.0M | $1.0M | ||
| Other Operating Expenses | $500 | $500.0K | $38.4M | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-25.7M | $-34.7M | $-38.4M | $-33.4M | ||
| EBITDA | $-35.9M | $-16.3M | $-39.6M | $-56.3M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | -- | $1.7M | $-2.6M | $-2.1M | ||
| Intinc | -- | $1.2M | $2.1M | $1.1M | ||
| Net Non-Operating Interest Income/Expense | -- | $490.0K | $2.1M | $1.1M | ||
| Gain on Sale of Securities | $-53.0K | $-490.0K | -- | -- | ||
| Other Income/Expense | $10.4M | $16.4M | $-966.0K | $20.8M | ||
| Other Special Charges | $-10.3M | $16.4M | $966.0K | $-20.8M | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | -- | -- | $700.0K | -- | ||
| Special Income Charges | -- | -- | $-700.0K | -- | ||
| Other Impairment Of Capital Assets | -- | -- | $400.0K | $41.0K | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-36.1M | $-17.1M | $-40.5M | $-57.3M | ||
| Pre-Tax Income | $-36.1M | $-18.8M | $-35.3M | $-55.2M | ||
| NET INCOME | ||||||
| Net Income | $-36.1M | $-18.8M | $-37.9M | $-55.2M | ||
| Net Income (Continuing Operations) | $-36.1M | $-18.8M | $-37.9M | $-55.2M | ||
| Net Income (Discontinued Operations) | $-36.1M | $-18.8M | $-37.9M | $-55.2M | ||
| Net Income (Common Stockholders) | $-36.1M | $-18.8M | $-37.9M | $-55.2M | ||
| Normalized Income | $-28.6M | -- | -- | $-52.5M | ||
| TOTALS | ||||||
| Total Expenses | $25.9M | $34.8M | $38.4M | $33.4M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $18.9M | $28.8M | $28.9M | $31.7M | ||
| Average Shares Outstanding (Diluted) | -- | $28.8M | $28.9M | $31.7M | ||
| Shares Outstanding | $28.7M | $28.9M | $29.3M | $47.2M | ||
| Basic EPS | $-1.91 | $-0.65 | $-1.31 | $-1.74 | ||
| Basic EPS (Continuing Operations) | $-1.91 | $-0.65 | $-1.31 | $-1.74 | ||
| Diluted EPS | $-1.91 | $-0.65 | $-1.31 | $-1.74 | ||
| Diluted EPS (Continuing Operations) | -- | $-0.65 | $-1.31 | $-1.74 | ||
| OTHER METRICS | ||||||
| Development Expense | -- | -- | $7.9M | $5.2M | ||
| Other Gand A | $10.7M | $14.1M | $13.9M | $14.1M | ||
| Restruct | -- | -- | $700.0K | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CADL | $5.38 | -3.6% | 837.42K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Candel Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW